Cel Sci CORP 10-Q quarterly reports

CEL-SCI Corporation's Q3 2026 10-Q filing reveals significant net losses and substantial doubt about its ability to continue as a going concern, despite promising clinical data for its lead drug candidate, Multikine.

CEL-SCI Corporation reported a reduced net loss for the nine months ended June 30, 2025, while advancing its Multikine immunotherapy toward a confirmatory registration study despite ongoing liquidity concerns.

CEL-SCI Corporation reports its financial results for the quarter ended March 31, 2025, highlighting its focus on advancing Multikine through a confirmatory registration study.

CEL-SCI Corporation reports its financial results for the quarter ended December 31, 2024, and provides an update on its clinical development program for Multikine.

CEL-SCI Corporation reported its financial results for the third quarter of 2024 and provided an update on its lead investigational therapy, Multikine, including plans for a confirmatory registration study.

CEL-SCI Corporation reported its financial results for the quarter ended March 31, 2024, and provided an update on its regulatory strategy for Multikine.

CEL-SCI Corporation reported its financial results for the quarter ended December 31, 2023, and provided updates on its regulatory strategy for Multikine.